Palbociclib and Pembrolizumab In Central Nervous System Metastases
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza nowotworu litego (Grupa 1) lub raka piersi (Grupa 2)
- •Co najmniej jedna zmiana w mózgu, którą można zmierzyć, o rozmiarze co najmniej 10 mm
- •Zmiana w mózgu, która się powiększa lub rozwija
- •Wiek powyżej 18 lat
- •Dobry stan zdrowia - możliwość wykonywania normalnych czynności (stan wg ECOG 0-2)
- •Prawidłowe wyniki krwi i funkcja nerek i wątroby
- •Zgodę na stosowanie antykoncepcji przez czas trwania badania i 6 miesięcy po jego zakończeniu
- •Podpisana zgoda na uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- March 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Trial contact
Priscilla Brastianos, MD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.